New Developments in Celiac Disease Treatment.
Study Goal
The researchers aimed to review the challenges and limitations of a gluten-free diet (GFD) for celiac disease (CD) patients and explore current pharmacological treatment research.
Results Summary
The study found that a GFD is difficult to maintain due to gluten contamination in foods, leading to persistent symptoms in one-third of adult patients and incomplete histological recovery in two-thirds. It also noted that a GFD may decrease quality of life for CD patients.
Population
Celiac disease patients, including both symptomatic and asymptomatic individuals.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
gluten-free diet (GFD) | no change | lifelong dietary restriction | all patients with CD | - | must endure | #1 |
gluten-free diet (GFD) | decrease | quality of life | CD patients | - | might be associated with decreased | #2 |
gluten-free diet (GFD) | increase | gluten contamination | celiac patients adhering to a GFD | four out of five | results in gluten contamination in the diet of | #3 |
gluten-free diet (GFD) | no change | persistent symptoms | one in three adult patients | one in three | will report persistent symptoms | #4 |
gluten-free diet (GFD) | no change | full histological recovery | two in three adult patients | two in three | will not achieve full histological recovery | #5 |
Celiac disease (CD) is a common autoimmune disease affecting around 1% of the population. It consists of an immune-mediated enteropathy, triggered by gluten exposure in susceptible patients. All patients with CD, irrespective of the presence of symptoms, must endure a lifelong gluten-free diet (GFD). This is not an easy task due to a lack of awareness of the gluten content in foods and the extensive incorporation of gluten in processed foods. Furthermore, a GFD imposes a sense of limitation and might be associated with decreased quality of life in CD patients. This results in gluten contamination in the diet of four out of five celiac patients adhering to a GFD. Furthermore, one in three adult patients will report persistent symptoms and two in three will not achieve full histological recovery when on a GFD. In recent years, there has been extensive research conducted in the quest to find the holy grail of pharmacological treatment for CD. This review will present a concise description of the current rationale and main clinical trials related to CD drug therapy.